Efficacy of erlotinib in patients with advanced non-small cell lung cancer: A pooled analysis of randomized trials

Anti-Cancer Drugs

Volumn 22, Issue 9, 2011, Pages 842-852

  Gao, Hui ^a   Ding, Xin ^a   Wei, Dong ^a   Cheng, Peng ^a   Su, Xiaomei ^a   Liu, Huanyi ^a   Aziz, Fahad ^b   Wang, Daoyuan ^a   Zhang, Tao ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

advanced non small cell lung cancer; erlotinib; pooled analysis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DACOMITINIB; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; VANDETANIB;

ADVANCED CANCER; ADVANCED NON SMALL CELL LUNG CANCER; ADVERSE OUTCOME; ANEMIA; ANOREXIA; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SURVIVAL; DATA EXTRACTION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OBJECTIVE RESPONSE RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052441197     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328349c303     Document Type: Review

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008 CA Cancer J Clin 2008; 58:71-96
2. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M, et al. Addition of platinum compounds to a new agent in patients with advanced non-smallcell lung cancer: a literature based meta-analysis of randomized trials. Ann Oncol 2004; 15:1782-1789 (Pubitemid 40012244)
3. Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapy in non-small cell lung cancer: are we making progress? J Thorac Dis 2011; 3:19-29
4. Shash E, Peccatori FA, Azim Jr HA. Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC).J Thorac Dis 2011; 3:57-64
5. Méndez M, Custodio A, Provencio M. New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis 2011; 3:30-56
6. Fontanini G, De Laurentiis M, Vignati S, Chinè S, Lucchi M, Silvestri V, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4:241-249 (Pubitemid 28062903)
7. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95:851-867 (Pubitemid 36833877)
8. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28:744-752
9. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005; 11:1572-1578 (Pubitemid 40315242)
10. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004; 6:s20-s23
11. Miller VA, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).J Clin Oncol 2009; 27:18s (suppl; abstr LBA8002).
12. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995; 16:62-73
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558 (Pubitemid 34746062)
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188 (Pubitemid 17189972)
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634 (Pubitemid 27387172)
17. Parmar MB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival end points. Stat Med 1998; 17:2815-2834 (Pubitemid 28562978)
18. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-1552 (Pubitemid 46733081)
19. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall- cell lung cancer. J Clin Oncol 2005; 23:5892-5899
20. Lee S, Rudd R, Khan I, Upadhyay S, Lewanski CR, Falk. S, et al. TOPICAL: randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010; 28:15s(suppl; abstr 7504).
21. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 J Clin Oncol 2008; 26:863-869 (Pubitemid 351398077)
22. Reck M, Von Pawel J, Fischer JR, Kortsik C, Bohnet S, von Eiff M, et al. Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): a randomized phase II study of the German Thoracic Oncology Working Group. J Clin Oncol 2010; 28:15s(suppl; abstr 7565).
23. Cappuzzo F, Coudert B, Wierzbicki R, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521-529
24. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:5080-5087
25. Perol M, Chouaid C, Milleron BJ, Gervais R, Barlesi F, Westeel. V, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010; 28:15s(suppl; abstr 7507).
26. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lungcancer. N Engl J Med 2005; 353:123-132 (Pubitemid 41058344)
27. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-4750. (Pubitemid 350086476)
28. Vamvakas L, Agelaki S, Kentepozidis NK, Karampeazis A, Pallis AG, Christophyllakis C, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol 2010; 28:15s(suppl; abstr 7519).
29. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059-1066
30. Boyer MJ, Blackhall FH, Park K, Barrios CH, Krzakowski MJ, Taylor I, et al. Efficacy and safety of PF299804 vs erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).J Clin Oncol 2010; 28:18s(suppl; abstr LBA7523).
31. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7:1850-1855 (Pubitemid 32994816)
32. Clarke MJ, Stewart LA. . Obtaining individual patient data from randomized controlled trials. In: Egger M, Smith GD, Altman DG, editors. Systematic Reviews in Health Care. 2001; London: BMJ Publishing Group, pp. 109-121
33. Bria E, Gralla RJ, Raftopoulos H, Giannarelli D. Comparing two methods of meta-analysis in clinical research - individual patient data-based (IPD) and literature-based abstracted data (AD) methods: analyzing five oncology issues involving more than 10 000 patients in randomized clinical trials (RCTs).J Clin Oncol 2007; 25:s6512
34. Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:264-270.
35. Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 2008; 9:235-238
36. Gridelli C, Rossi A, Mongillo F, Bareschino M, Maione P, Ciardiello F. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. ClinLung Cancer 2007; 8:396-398 (Pubitemid 46918286)
37. Chen Y, Tsai C, Shih J, Perng R,Whang-Peng J. Phase II randomized trial of erlotinib versus vinorelbine in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) aged Z70 years in Taiwan. J Clin Oncol 2009; 27:s8051
38. Stinchcombe T, Bradford DS, Lee CB, Moore DT, Bakri KM, Taylor MA, et al. Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).J Clin Oncol 2010; 28:15s(suppl; abstr 7576).
39. Ahn J, Kim S, Ahn M, Lee J, Uhm J, Sun J, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. J Clin Oncol 2010; 28:15s(suppl; abstr 7551).